Europe Preclinical Cro Market Size & Outlook, 2023-2030
Europe preclinical cro market, 2018-2030 (US$M)
Related Markets
Europe preclinical cro market highlights
- The Europe preclinical cro market generated a revenue of USD 1,803.8 million in 2023.
- The market is expected to grow at a CAGR of 7% from 2024 to 2030.
- In terms of segment, toxicology testing was the largest revenue generating service in 2023.
- Bioanalysis and DMPK studies is the most lucrative service segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 1,803.8 million |
| Market revenue in 2030 | USD 2,890.7 million |
| Growth rate | 7% (CAGR from 2023 to 2030) |
| Largest segment | Toxicology testing |
| Fastest growing segment | Bioanalysis and DMPK studies |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology |
| Key market players worldwide | Eurofins Scientific SE, Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc, Intertek Group PLC, Labcorp Holdings Inc, Crown Bioscience, SGA |
Other key industry trends
- In terms of revenue, Europe region accounted for 31.6% of the global preclinical cro market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,865.2 million by 2030.
Toxicology testing was the largest segment with a revenue share of 26.14% in 2023. Horizon Databook has segmented the Europe preclinical cro market based on bioanalysis and dmpk studies, toxicology testing, compound management, chemistry, safety pharmacology covering the revenue growth of each sub-segment from 2018 to 2030.
Europe holds the second largest share in the global preclinical trial outsourcing market owing to the presence of major biopharmaceutical companies such as F. Hoffmann-La Roche Ltd, and Novartis in this region.
As preclinical testing is generally conducted in proximity to central drug development centers, outsourcing preclinical trial services to local CROs present in the region is expected to increase, which is expected to further contribute to the growth of preclinical trial outsourcing in this region.
In addition, a large number of CROs specializing in early drug discovery, such as Charles River Laboratories and LabCorp, have their centers in European countries like the UK, Germany, and France, which is expected to contribute to market growth in this region.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Preclinical CRO Market Scope
Preclinical CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe preclinical cro market size, by country, 2018-2030 (US$M)
Europe Preclinical CRO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
